CSF2 and osteosarcoma: Limited to no toxicity observed one patient with EWS2 achieved a CR3; 3-year EFS4 and OS5 were 7.8 and 35.4%, respectivelyEFS for 96 patients with osteosarcoma 12% at 4 months; EFS for 42 evaluable patients 20% at 12 months5-year EFS of non-metastatic EWS patients in group A (with GM-CSF); 0.56 vs 5-year EFS in group B (without GM-CSF 0.51. EFS for metastatic EWS was not calculated due to small numbers